Scicluna, Rhianne L.
Everett, Nicholas A.
Badolato, Connie J.
Wilson, Bianca B.
Bowen, Michael T.
Funding for this research was provided by:
University of Sydney
Article History
Received: 6 June 2023
Accepted: 10 April 2024
First Online: 27 April 2024
Change Date: 6 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00213-024-06605-w
Declarations
:
: In addition to his academic role, Associate Professor Michael Bowen is co-founder and Chief Scientific Officer of Kinoxis Therapeutics Pty Ltd, an Australian-based company developing novel small molecule treatments for brain disorders, including the treatment of opioid withdrawal and Associate Professor Michael Bowen receives research funding from Kinoxis Therapeutics. This industry work does not involve the research presented in this manuscript. Rhianne Scicluna, Nicholas Everett, Connie Badolato and Bianca Wilson do not have any conflicts of interest.